News and Materials

  • News
    RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212

    11/01/2016

    RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212

    Read more
    AREVA Med appoints Julien Dodet as new Chief Executive Officer

    08/01/2016

    AREVA Med appoints Julien Dodet as new Chief Executive Officer

    Read more
    Nordic Nanovector and AREVA Med to investigate potential of  lead-212 conjugated anti-CD37 antibody for treating leukaemias

    06/28/2016

    Nordic Nanovector and AREVA Med to investigate potential of  lead-212 conjugated anti-CD37 antibody for treating leukaemias

    Read more
    AREVA Med Inaugurates Second Lead-212 Production Facility

    04/13/2016

    AREVA Med Inaugurates Second Lead-212 Production Facility

    Read more
    Limoges: Another milestone achieved for the CARAT project in cancer research

    03/31/2016

    Limoges: Another milestone achieved for the CARAT project in cancer research

    Read more
    Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies

    03/31/2016

    Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies

    Read more
    AREVA Med Partners with Art Institute of Dallas (U.S.) and École Supérieure de Design Troyes (France)

    02/29/2016

    AREVA Med Partners with Art Institute of Dallas (U.S.) and École Supérieure de Design Troyes (France)

    Read more
    AREVA Med’s Second Production Facility  on Schedule to Open in 2nd Quarter of 2016

    01/21/2016

    AREVA Med’s Second Production Facility  on Schedule to Open in 2nd Quarter of 2016

    Read more
    AREVA Med Launches Construction in the U.S. of Second Facility to Produce Lead-212 Used for Developing Cancer Treatments

    09/09/2015

    AREVA Med Launches Construction in the U.S. of Second Facility to Produce Lead-212 Used for Developing Cancer Treatments

    Read more
    Bpifrance to support AREVA Med and its partners in developing new lead-212 treatments for cancer

    07/01/2015

    Bpifrance to support AREVA Med and its partners in developing new lead-212 treatments for cancer

    Read more
    AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors

    05/18/2015

    AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors

    Read more
    AREVA Med Receives CEO Cancer Gold Standard Accreditation

    03/17/2015

    AREVA Med Receives CEO Cancer Gold Standard Accreditation

    Read more
    AREVA Med to expand production capacities in the U.S.

    11/03/2014

    AREVA Med to expand production capacities in the U.S.

    Read more
    Macrocyclics introduces new offices in Asia and Europe

    07/07/2014

    Macrocyclics introduces new offices in Asia and Europe

    Read more
    AREVA Med selects Caen for its future lead-212 production facility

    02/12/2014

    AREVA Med selects Caen for its future lead-212 production facility

    Read more
    Macrocyclics introduces new products

    01/10/2014

    Macrocyclics introduces new products

    Read more
    AREVA Med launches production of lead-212 at new facility

    11/21/2013

    AREVA Med launches production of lead-212 at new facility

    Read more
    AREVA Med – Roche Partnership: the common research laboratory aiming to develop new radio-immunotherapy treatments for cancer is operational

    09/20/2013

    AREVA Med – Roche Partnership: the common research laboratory aiming to develop new radio-immunotherapy treatments for cancer is operational

    Read more
    Macrocyclics to Collaborate with Roche on Molecular Innovation for Nuclear Medicine

    05/22/2013

    Macrocyclics to Collaborate with Roche on Molecular Innovation for Nuclear Medicine

    Read more
    AREVA Med Presents Pharmacokinetics Data from Phase 1 Clinical Trial at SNMMI

    05/16/2013

    AREVA Med Presents Pharmacokinetics Data from Phase 1 Clinical Trial at SNMMI

    Read more
    The Ecole Supérieure de Design de Troyes and AREVA Med sign a partnership agreement for the industrialization of new equipment to be used in the fight against cancer

    09/19/2012

    The Ecole Supérieure de Design de Troyes and AREVA Med sign a partnership agreement for the industrialization of new equipment to be used in the fight against cancer

    Read more
    Roche and AREVA Med join forces in the fight against cancer and create  a novel radio-immunotherapy

    07/27/2012

    Roche and AREVA Med join forces in the fight against cancer and create  a novel radio-immunotherapy

    Read more
    AREVA Med’s Clinical Trial Now Enrolling Patients at UAB Affiliates

    05/03/2012

    AREVA Med’s Clinical Trial Now Enrolling Patients at UAB Affiliates

    Read more
    AREVA Med acquires Macrocyclics, Inc.

    10/20/2011

    AREVA Med acquires Macrocyclics, Inc.

    Read more
    AREVA Med initiates Phase I Clinical Trial of anti-cancer treatment with lead-212

    08/08/2011

    AREVA Med initiates Phase I Clinical Trial of anti-cancer treatment with lead-212

    Read more
    AREVA Med Initiates Phase 1 Clinical Trial of ²¹²Pb-TCMC-Trastuzumab in Patients with HER-2 Positive Intra-abdominal Cancers

    08/04/2011

    AREVA Med Initiates Phase 1 Clinical Trial of ²¹²Pb-TCMC-Trastuzumab in Patients with HER-2 Positive Intra-abdominal Cancers

    Read more
    AREVA Med initiates Phase I Clinical Trial of anti-cancer treatment with lead-212

    07/12/2011

    AREVA Med initiates Phase I Clinical Trial of anti-cancer treatment with lead-212

    Read more
    Treatment against cancer: AREVA launches construction of the Maurice Tubiana laboratory

    05/31/2011

    Treatment against cancer: AREVA launches construction of the Maurice Tubiana laboratory

    Read more
    The “public hearing” period for the construction of AREVA Med’s new 212Pb production facility was successfully completed

    04/07/2011

    The “public hearing” period for the construction of AREVA Med’s new 212Pb production facility was successfully completed

    Read more
    AREVA Receives Landmark Authorization to Initiate Clinical Trials for Promising Anticancer Treatment

    01/25/2011

    AREVA Receives Landmark Authorization to Initiate Clinical Trials for Promising Anticancer Treatment

    Read more
    Cancer treatments: AREVA and Inserm sign a research agreement

    01/11/2011

    Cancer treatments: AREVA and Inserm sign a research agreement

    Read more
    AREVA Med Forms High Level Science Advisory Committee

    08/25/2010

    AREVA Med Forms High Level Science Advisory Committee

    Read more
    AREVA Signs Research Agreement with the University of Cincinnati for New Cancer Treatment

    04/13/2010

    AREVA Signs Research Agreement with the University of Cincinnati for New Cancer Treatment

    Read more
    Anticancer Treatments: AREVA to Build Isotope Production Facility

    03/10/2010

    Anticancer Treatments: AREVA to Build Isotope Production Facility

    Read more
    AREVA Nuclear Medicine Efforts Recognized by the Clinton Global Initiative

    09/24/2009

    AREVA Nuclear Medicine Efforts Recognized by the Clinton Global Initiative

    Read more
    AREVA Forms Subsidiary To Develop New Cancer Treatments

    05/08/2009

    AREVA Forms Subsidiary To Develop New Cancer Treatments

    Read more
    AREVA Signs Cooperative Research and Development Agreement with the U.S. National Cancer Institute for New Cancer Treatment

    06/11/2008

    AREVA Signs Cooperative Research and Development Agreement with the U.S. National Cancer Institute for New Cancer Treatment

    Read more
  • Brochures

    AREVA Med Brochure

    Macrocyclics 2017 Product Catalog

  • Videos
    Video

    AREVA Med:  Developing Nuclear Medicine for Tomorrow’s Cancer Treatments

    AREVA Med is a nuclear biotech company developing innovative therapies in oncology. AREVA Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells. With its partners, AREVA Med pursues the development of effective therapies to address cancer patients’ needs. AREVA Med is the medical subsidiary of the AREVA group.

  • Events
    EANM - European Association of Nuclear Medicine - 2017

    EANM - European Association of Nuclear Medicine - 2017

    October 21-25, 2017, Vienna, Austria

    Read more
    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2017

    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2017

    June 10 - 14, 2016, Denver, Colorado

    Read more
    TAT10 - 10th International Symposium on Targeted Alpha Therapies

    TAT10 - 10th International Symposium on Targeted Alpha Therapies

    May 30 - June 1, 2017, Kanazawa, Japan

    Read more
    EANM - European Association of Nuclear Medicine - 2016

    EANM - European Association of Nuclear Medicine - 2016

    October 15-19, 2016, Barcelona, Spain

    Read more
    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2016

    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2016

    June 11 - 15, 2016, San Diego, California

    Read more
    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2015

    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2015

    June 6 - 10, 2015     Baltimore, Maryland

    Read more
    9th Symposium on Targeted Alpha Therapy

    9th Symposium on Targeted Alpha Therapy

    May 19 - 21, 2015      Warsaw, Poland

    Read more
    ANIMMA 2015 - Advancements in Nuclear Instrumentation Measurement Methods and their Applications

    ANIMMA 2015 - Advancements in Nuclear Instrumentation Measurement Methods and their Applications

    April 20 - 24, 2015     Lisbon, Portugal

    Read more
    Society of Gynecologic Oncology - 2015 Annual Meeting on Women's Cancer

    Society of Gynecologic Oncology - 2015 Annual Meeting on Women's Cancer

    March 28 - 31, 2015     Chicago, Illinois

    Read more
    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2014

    SNMMI - Society of Nuclear Medicine and Molecular Imaging - 2014

    June 7 - 14, 2014     St. Louis, Missouri

    Read more
    TAT - 12th International Congress on Targeted Anticancer Therapies

    TAT - 12th International Congress on Targeted Anticancer Therapies

    March 5 - 7, 2014     Washington, DC

    Read more
    ASTRO - American Society for Radiation Oncology - 2013 Annual Meeting

    ASTRO - American Society for Radiation Oncology - 2013 Annual Meeting

    September 22 - 25, 2013     Atlanta, Georgia

    Read more
    WIPR 2013

    WIPR 2013

    July 9 - 12, 2013     Nantes, France

    Read more
    SNM - Society of Nuclear Medicine and Molecular Imaging - 2013

    SNM - Society of Nuclear Medicine and Molecular Imaging - 2013

    June 8 -12, 2013     Vancouver, BC - Canada

    Read more
    EMIT - Targeted Radiotherapy

    EMIT - Targeted Radiotherapy

    January 30 - 31, 2013     Washington, DC

    Read more
  • Scientific Publications
    Safety and Outcome Measures of First-in-Human Intraperitoneal Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab <sup>212</sup>Pb-TCMC-Trastuzumab

    Safety and Outcome Measures of First-in-Human Intraperitoneal Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab 212Pb-TCMC-Trastuzumab

    Read more
    Toxicological Studies of Lead-212 Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

    Toxicological Studies of Lead-212 Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

    Read more
    Dose Escalation and Dosimetry of First-in-Human Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

    Dose Escalation and Dosimetry of First-in-Human Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

    Read more
    Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

    Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

    Read more
    Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

    Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

    Read more
    Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

    Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

    Read more
    212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint

    212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint

    Read more
    Developing 212Pb Based RICs as Powerful Targeted Therapies

    Developing 212Pb Based RICs as Powerful Targeted Therapies

    Read more
    Biodistribution of 212Pb conjugated trastuzumab in mice

    Biodistribution of 212Pb conjugated trastuzumab in mice

    Read more
    Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice

    Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice

    Read more
    Radiolabeling and Imaging of 212Pb-TCMC-Trastuzumab

    Radiolabeling and Imaging of 212Pb-TCMC-Trastuzumab

    Read more
AREVA Med Video

Click here to view the latest AREVA Med Video

Contact

For more information about AREVA Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673